Cancer News

Keytruda plus Lenvima Approved for Certain Patients with Uterine Cancer (09/19/2019)

The United States Food and Drug Administration (FDA) granted accelerated approval to the combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and are not candidates for curative surgery or radiation. The 111/KEYNOTE-146 single-arm clinical trial... Continue Reading

GARNET Study Suggets Dostarlimab Promising for Uterine/Endometrial Cancer (03/28/2019)

An early phase clinical trial evaluating dostarlimab in women with recurrent or advanced endometrial cancer appears promising.  These data were presented at the 2019 Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Honolulu, Hawaii. Endometrial cancer (EC) is the most common gynaecologic malignancy in the U.S. but there are limited treatment options... Continue Reading

Precision Cancer Treatment with Afinitor Encouraging in Uterine Cancer (04/04/2018)

CancerConnect News: Combination therapy with Afinitor (everolimus) and Femara (letrozole) demonstrated encouraging activity in the treatment of advanced endometrial cancer, according to a report from the Society of Gynecologic Oncologists meeting this week. About Uterine (Endometrial) Cancer Uterine cancer is one of the most common gynecologic cancers in women, with more than 67,000 individuals diagnosed …

Continue reading "Precision Cancer Treatment with Afinitor Encouraging in Uterine Cancer"

Uterine Cancer: The Next Immunotherapy Frontier? (01/30/2018)

CancerConnect News: All gynecologic cancers are challenging to treat. They can be hard to find and are usually diagnosed when they are advanced. Although these cancers can be held at bay with surgery or chemotherapy, they often return and become difficult to control. Researchers at Memorial Sloan Kettering are exploring whether harnessing the power of …

Continue reading "Uterine Cancer: The Next Immunotherapy Frontier?"